Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04314219 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients

Study acronym: PTCy-PMAT
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 13, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Identification, Study Status, Oversight, IPDSharingv4
  2. Primary completion date: Jan 23, 2025 to Dec 2025
    • Study completion date: Dec 29, 2026 to Dec 2026
    • Eligibility criteria expanded, about 1 word
    v3
  3. Primary completion date: Feb 23, 2024 to Jan 23, 2025
    • Start date: Feb 23, 2020 to Aug 15, 2021
    • Study completion date: Dec 29, 2025 to Dec 29, 2026
    • Study title shortened, about 2 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized clinical trial will evaluate two approaches of GvHD prophylaxis; the standard of care GVHD prophylaxis regimen (methotrexate/calcineurin inhibitors) and post-transplant cyclophosphamide with calcineurin inhibitors for their efficacy as a new GVHD prophylaxis strategy.
Trial Details
NCT Number NCT04314219
Lead Sponsor King Faisal Specialist Hospital & Research Center
Conditions
(from sponsor)		 Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid Leukemia (AML) in Remission
Related terms Leukemia, Myeloid, Acute, Pathologic Complete Response, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 264 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov